Heron Therapeutics Inc (HRTX)
2.59
-0.05
(-1.89%)
USD |
NASDAQ |
Apr 22, 16:00
2.71
+0.12
(+4.63%)
Pre-Market: 09:08
Heron Therapeutics Net Income (Quarterly): -10.72M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -10.72M |
| September 30, 2023 | -25.01M |
| June 30, 2023 | -42.06M |
| March 31, 2023 | -32.77M |
| December 31, 2022 | -19.87M |
| September 30, 2022 | -41.91M |
| June 30, 2022 | -56.36M |
| March 31, 2022 | -63.89M |
| December 31, 2021 | -54.65M |
| September 30, 2021 | -52.41M |
| June 30, 2021 | -61.02M |
| March 31, 2021 | -52.61M |
| December 31, 2020 | -62.28M |
| September 30, 2020 | -58.23M |
| June 30, 2020 | -55.19M |
| March 31, 2020 | -51.58M |
| December 31, 2019 | -57.92M |
| September 30, 2019 | -33.60M |
| June 30, 2019 | -50.22M |
| March 31, 2019 | -63.01M |
| December 31, 2018 | -49.56M |
| September 30, 2018 | -38.35M |
| June 30, 2018 | -38.67M |
| March 31, 2018 | -52.26M |
| December 31, 2017 | -62.49M |
| Date | Value |
|---|---|
| September 30, 2017 | -41.87M |
| June 30, 2017 | -42.80M |
| March 31, 2017 | -50.33M |
| December 31, 2016 | -47.96M |
| September 30, 2016 | -48.51M |
| June 30, 2016 | -43.23M |
| March 31, 2016 | -33.44M |
| December 31, 2015 | -31.24M |
| September 30, 2015 | -22.67M |
| June 30, 2015 | -23.11M |
| March 31, 2015 | -20.57M |
| December 31, 2014 | -20.62M |
| September 30, 2014 | -19.19M |
| June 30, 2014 | -19.01M |
| March 31, 2014 | -17.54M |
| December 31, 2013 | -14.04M |
| September 30, 2013 | -12.87M |
| June 30, 2013 | -15.41M |
| March 31, 2013 | -12.95M |
| December 31, 2012 | -7.737M |
| September 30, 2012 | -6.121M |
| June 30, 2012 | -4.569M |
| March 31, 2012 | -4.921M |
| December 31, 2011 | -4.261M |
| September 30, 2011 | -4.202M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-63.89M
Minimum
Mar 2022
-10.72M
Maximum
Dec 2023
-46.44M
Average
-52.41M
Median
Sep 2021
Net Income (Quarterly) Benchmarks
| United Therapeutics Corp | 217.10M |
| Esperion Therapeutics Inc | -56.34M |
| Aldeyra Therapeutics Inc | -4.753M |
| Ocular Therapeutix Inc | -29.22M |
| Clearside Biomedical Inc | -4.832M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 34.23M |
| Total Expenses (Quarterly) | 44.45M |
| EPS Diluted (Quarterly) | -0.05 |
| Enterprise Value | 482.70M |
| Gross Profit Margin (Quarterly) | 71.12% |
| Profit Margin (Quarterly) | -31.33% |
| Earnings Yield | -32.43% |
| Normalized Earnings Yield | -32.43 |